Stanley Chang

Title: Innovations by Stanley Chang in Cancer Treatment

Introduction

Stanley Chang is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in cancer treatment. With a total of two patents to his name, his work focuses on innovative methods for diagnosing and treating hepatocellular carcinoma.

Latest Patents

Chang's latest patents include groundbreaking research on Muparfostat. This invention is aimed at treating patients with hepatitis virus-related hepatocellular carcinoma after surgical resection. The patent details methods for reducing intrahepatic tumor recurrence and increasing the disease-free survival period in patients with microvascular invasion. It specifically excludes patients without vascular invasion and those with macrovascular invasion. Additionally, his research identifies the cancer-specific gene MH15 as an oncogene. The patents also provide methods and compositions for detecting and diagnosing cancer by determining the level of MH15 expression in biological samples. Furthermore, they include methods for screening inhibitors and moderators of MH15 expression and activity, which can lead to new cancer treatments.

Career Highlights

Stanley Chang is associated with Medigen Biotechnology Corporation, where he continues to advance his research in cancer therapies. His work has garnered attention for its potential impact on patient outcomes in hepatocellular carcinoma treatment.

Collaborations

Chang collaborates with esteemed colleagues such as Hsun-Lang Chang and Wei-Ying Kuo, contributing to a dynamic research environment focused on innovative cancer solutions.

Conclusion

Stanley Chang's contributions to cancer treatment through his patents and research at Medigen Biotechnology Corporation highlight his role as a leading inventor in the field. His work promises to enhance the understanding and treatment of hepatocellular carcinoma, ultimately benefiting patients worldwide.